BURLINGTON, N.C., May 13, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit for ages 2-17. The authorization expands the use of Pixel by Labcorp to children and adolescents 2 years of age and older when purchased by a parent or guardian.
COVID-19 News
View our latest news about advancements in health science, COVID-19, and more.
Jun 14 2022
Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
BURLINGTON, N.C., June 14, 2022 — On Friday, June 10, 2022, Labcorp, a global life sciences company, received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II sequencing system.
Read more about Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
May 18 2022
Labcorp Receives Emergency Use Authorization for First Non-Prescription At-Home Collection Kit for Combined COVID-19, Flu and RSV Detection
BURLINGTON, N.C., May 18, 2022 — Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.
Nov 30 2021
Labcorp Now Offers Observed Collection for COVID-19 PCR Testing in Over 500 Locations Nationwide, with Plans to Expand to More Than 1,000 Locations
BURLINGTON, N.C., Nov. 30, 2021 — Labcorp (NYSE: LH), a global life sciences company, is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure. By mid-December, the company plans to further expand the COVID-19 PCR test collection service to over 1,000 locations.
Oct 1 2021
Labcorp Receives Emergency Use Authorization for At Home Collection Kit for Combined COVID-19 and Flu Detection
BURLINGTON, N.C., Oct. 1, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider.
Jul 1 2021
Labcorp Extends COVID-19 Genomic Sequencing Work With The CDC
BURLINGTON, N.C., June 30, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced the extension of its work with the U.S. Centers for Disease Control and Prevention (CDC) to help identify and monitor variants of SARS-CoV-2, the virus that causes COVID-19.
Jun 22 2021
Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance
Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples. This sequencing is being performed as part of a U.S. Centers for Disease Control and Prevention (CDC) effort to identify and track the spread of SARS-CoV-2 variants throughout the country.
Jun 16 2021
NCDHHS Expands Home Testing Program to All Eligible North Carolinians
The North Carolina Department of Health and Human Services today announced the state is expanding availability of its at-home COVID-19 test collection. Any North Carolina resident may receive a Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit that is shipped overnight directly to their homes at no cost. Tests can be used on people age 2 and up.
May 25 2021
Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection
BURLINGTON, N.C.--(BUSINESS WIRE)--May 24, 2021-- Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.
May 11 2021
Labcorp and the U.S. Department of Health and Human Services Join Forces to Raise Awareness of COVID-19 Treatments
BURLINGTON, N.C., May 11, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, is working with the U.S. Department of Health and Human Services (HHS) to raise awareness of potentially lifesaving monoclonal antibody COVID-19 therapies.
Apr 20 2021
Labcorp Launches COVID-19 Test Kits For Small Businesses to Support Return to Work and Life Safely
BURLINGTON, N.C. — Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of the Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit for small businesses, an initiative aimed at providing fast, convenient, and reliable testing for companies with as many as 120 employees. Labcorp Employer Services currently provides COVID-19 testing and vaccination services for larger organizations and communities.
Mar 26 2021
NCDHHS Pilots Home Testing Program with Labcorp to Increase Access to Testing
RALEIGH — While vaccine supplies are limited, it is important North Carolinians continue practicing the 3Ws and get tested for COVID-19 if they have symptoms or have been in close contact to someone with COVID-19.
Feb 24 2021
Walgreens to Make Pixel by Labcorp™ COVID-19 PCR Test Home Collection Kit Available Over-The-Counter at Stores Nationwide
Kit to be available for purchase at Walgreens without a prescription and will allow for greater access to testing, helping reduce the spread of COVID-19 and improve the health of communities
Labcorp's COVID-19 PCR Testing
1-2 Days
Average Time to Result from Specimen Pickup
70.6M
Molecular Tests Performed
275K
Molecular Test Capacity Per Day*
8.9M
Antibody Tests Performed
300K
Antibody Test Capacity Per Day*
$0
Tests Offered with No Upfront Costs**
Stats updated as of June 30, 2022. COVID-19 volumes are U.S. and Canada volumes and are consistent with the figures provided in the company’s quarterly financial results. Prior volumes published on the website were U.S. only. Future COVID-19 test volumes will be updated quarterly after the release of Labcorp’s quarterly earnings results.
*Capacity numbers are subject to sufficient labor, equipment and supplies
**Labcorp remains committed to providing access to COVID-19 tests without incurring upfront costs for as many people as possible. The cost of our COVID-19 test is set by the Centers for Medicare and Medicaid Services. For people with insurance, Labcorp bills the insurance plans or government agency for reimbursement. For individuals without insurance or health care coverage, the cost of the test is billed to the individual by Labcorp at the same rate paid by Medicare to laboratories for COVID testing. A $6 non-refundable physician fee is charged for the IgG antibody test if it is requested through Labcorp.com.
Tracking COVID-19 Variants
Labcorp has been regularly tracking variants of the virus throughout the pandemic. The sensitivity of our PCR test is not impacted by these variants. We have been working with the Centers for Disease Control and Prevention (CDC) to provide sequencing of samples of SARS-CoV-2, the virus that causes COVID-19. Our tests remain effective against variants like Omicron and Delta. This is because they are designed to identify segments of the genetic code that are the least likely to mutate. For more information on variants, see our Viral Variation 101 post or read our Guide to Variants.
Total number of samples sequenced
402,000 as of June 30, 2022
Data covers the U.S. including the District of Columbia and Puerto Rico
Labcorp PCR Test performance confirmed
Alpha (B.1.1.7, Q.1-Q.8)
Beta (B.1.351, B.1.351.2, B.1.351.3)
Delta (B.1.617.2)
Epsilon (B.1.427, B.1.429)
Eta (B.1.525)
Gamma (P.1, P.1.1, P.1.2)
Iota (B.1.526)
Kappa (B.1.617.1)
Lambda (C.37)
Mu (B.1.621)
Omicron (B.1.1.529, BA.2, BA.4, BA.5)
Zeta (P.2)
For more information visit US COVID-19 Cases Caused by Variants on the CDC website.
Media Information
Digital Assets
If you use any of this imagery or footage, please use Photo/Video credit: Labcorp
Download B-roll
Download Images